Trial Profile
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms EarLEE-2
- Sponsors Novartis Pharmaceuticals
- 15 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Nov 2017 According to a Novartis media release, data from this trial will be presented at the upcoming 40th annual San Antonio Breast Cancer Symposium (SABCS).
- 02 Oct 2017 Planned End Date changed from 22 Sep 2025 to 17 Nov 2025.